GLP-1 Market
LLY $1123.00 ▼ -0.1% NVO $44.01 ▼ -1.2% PFE $27.65 ▼ -0.5% VKTX $32.13 ▼ -1.7% KLRA $14.91 ▲ +0.5% GPCR $39.55 ▼ -4.1% RHHBY $53.19 ▼ -0.4% HIMS $27.44 ▼ -1.6% WW $14.78 ▼ -1.1%
Delayed · As of 9:20 AM

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

MEDI0382

Company
MedImmune LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
None currently listed

Efficacy results: Not yet reported

No recruiting studies currently listed

See all studies for this drug

Data source: ClinicalTrials.gov · trial data as of Sep 11, 2026

Trial details
  • Completed NCT NCT02394314

    A Phase 1, Single Dose Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Healthy Volunteers

    Not yet reported MedImmune LLC 362 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT02548585

    A Multiple-ascending-dose Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

    Not yet reported, Not yet reported MedImmune LLC 113 participants Est. completion 2017-02-24 11 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03235050

    A Study to Evaluate the Efficacy and Safety of MEDI0382 in the Treatment of Overweight and Obese Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 834 participants Est. completion 2019-06-14 119 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03235375

    A Study to Evaluate Pharmacokinetics, Safety and Tolerability of MEDI0382 in Renal Impairment Subjects

    Not yet reported MedImmune LLC 37 participants Est. completion 2018-04-24 4 sites Stand-alone
    Other conditions: Renal Insufficiency
    View official trial listing →
  • Completed NCT NCT03244800

    A Study to Investigate Different Doses of 0382 in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

    Not yet reported MedImmune LLC 65 participants Est. completion 2018-01-23 5 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03341013

    A Pilot Study Investigating Bioequivalence Between a Single Dose of Formulation 2 and Formulation 3 of MEDI0382

    Not yet reported MedImmune LLC 24 participants Est. completion 2018-01-29 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03347968

    Study to Compare Pharmacokinetics & Pharmacodynamics of Warfarin & Esmolol in the Absence & Presence of MEDI0382

    Not yet reported MedImmune LLC 22 participants Est. completion 2018-04-09 1 site Stand-alone
    Other conditions: Healthy Volunteers
    View official trial listing →
  • Completed NCT NCT03385369

    A Study to Evaluate the Safety and Pharmacokinetics of MEDI0382 in Overweight/Obese Subjects of Japanese or Chinese Descent

    Not yet reported MedImmune LLC 32 participants Est. completion 2018-04-12 1 site Stand-alone
    Other conditions: Safety, Healthy Subjects
    View official trial listing →
  • Completed NCT NCT03444584

    Study of MEDI0382 in Combination With Dapagliflozin and Metformin in Overweight/Obese Participants With Type 2 Diabetes

    Not yet reported MedImmune LLC 49 participants Est. completion 2018-12-06 8 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03550378

    A Study to Look at the Effect MEDI0382 Has on Blood Sugar in People With Type 2 Diabetes and Kidney Problems and Also to Check That MEDI0382 is Well Tolerated

    Not yet reported MedImmune LLC 41 participants Est. completion 2019-02-04 7 sites Stand-alone
    Other conditions: Type II Diabetes Mellitus, Renal Insufficiency
    View official trial listing →
  • Completed NCT NCT03555994

    A Study to Investigate the Effect of MEDI0382 on Hepatic Glycogen Metabolism in Overweight and Obese Subjects With Type 2 Diabetes Mellitus.

    Not yet reported MedImmune LLC 51 participants Est. completion 2021-04-14 3 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03596177

    A Study to Evaluate the Effect of MEDI0382 on Energy Balance in Overweight and Obese Participants With Type 2 Diabetes Mellitus

    Not yet reported MedImmune LLC 28 participants Est. completion 2019-12-22 1 site Stand-alone
    Other conditions: Diabetes Mellitus, Type II, Obesity
    View official trial listing →
  • Completed NCT NCT03625778

    A Study to Assess Safety, Tolerability, and Pharmacokinetics of MEDI0382 in Non-diabetic Obese Participants

    Not yet reported MedImmune LLC 51 participants Est. completion 2019-08-25 2 sites Stand-alone
    Other conditions: Obesity
    View official trial listing →
  • Completed NCT NCT03645421

    Safety and Tolerability Study of MEDI0382 in Japanese Preobese or Obese Subjects With Type 2 Diabetes

    Not yet reported AstraZeneca 61 participants Est. completion 2019-01-17 5 sites Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT03745937

    A Study to Evaluate the Safety and Tolerability of MEDI0382 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

    Not yet reported MedImmune LLC 20 participants Est. completion 2019-05-28 1 site Stand-alone
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04019561

    A Study to Evaluate Safety and Pharmacodynamic Efficacy of 0382 in Obese Subjects With NAFLD/NASH.

    Not yet reported MedImmune LLC 74 participants Est. completion 2021-05-06 27 sites Stand-alone
    MASLDMASH
    View official trial listing →
  • Completed NCT NCT04208620

    Safety and Tolerability Study of Cotadutide in Japanese Obese Subjects With Type 2 Diabetes Melitus

    Not yet reported AstraZeneca 16 participants Est. completion 2020-07-08 3 sites
    Type 2 diabetes
    View official trial listing →
  • Completed NCT NCT04515849

    A Study of Cotadutide in Participants Who Have Chronic Kidney Disease With Type 2 Diabetes Mellitus

    Not yet reported AstraZeneca 248 participants Est. completion 2022-03-08 83 sites
    Type 2 diabetesChronic kidney disease
    View official trial listing →
  • Completed NCT NCT05437848

    Chinese Multiple Dose Escalation (MDE) High Dose Study

    Not yet reported AstraZeneca 16 participants Est. completion 2022-12-12 2 sites
    Other conditions: Diabetes
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.